Caffeic Acid Phenethyl Ester and Therapeutic Potentials

Ghulam Murtaza, Sabiha Karim, Muhammad Rouf Akram, Shujaat Ali Khan, Saira Azhar, Amara Mumtaz, and Muhammad Hassham Hassan Bin Asad

1 Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan
2 University College of Pharmacy, University of Punjab, Lahore 54000, Pakistan
3 Department of Pharmacy, University of Sargodha, Sargodha 40100, Pakistan
4 Department of Chemistry, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan

Correspondence should be addressed to Ghulam Murtaza; gmdogar356@gmail.com and Sabiha Karim; sksabihakarim@gmail.com

Received 6 February 2014; Revised 2 April 2014; Accepted 14 April 2014; Published 29 May 2014

Academic Editor: George Perry

Copyright © 2014 Ghulam Murtaza et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Caffeic acid phenethyl ester (CAPE) is a bioactive compound of propolis extract. The literature search elaborates that CAPE possesses antimicrobial, antioxidant, anti-inflammatory, and cytotoxic properties. The principal objective of this review article is to sum up and critically assess the existing data about therapeutic effects of CAPE in different disorders. The findings elaborate that CAPE is a versatile therapeutically active polyphenol and an effective adjuvant of chemotherapy for enhancing therapeutic efficacy and diminishing chemotherapy-induced toxicities.

1. Introduction

Caffeic acid phenethyl ester (CAPE) is a natural bioactive compound. It occurs in many plants [1]. It is acquired from propolis obtained through extraction from honeybee hives [2]. The chemical name of CAPE is 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)acrylate. It is also termed as phenylethyl caffeate or phenethyl caffeate. Its molecular formula is C_{17}H_{16}O_{4} [3]. The chemical structure of CAPE is given in Figure 1. For the first time, Grunberger et al. identified this hydrophobic polyphenol [4]. This polyphenolic ester can also be synthesized by reacting caffeic acid with phenethyl alcohols [5–7]. CAPE is a polyphenol with hydroxyl groups within the catechol ring which is responsible for its crucial role in many biological activities [8]. The literature search showed an extensive research on the biological features of CAPE. The available studies narrate it as an effective moiety against various pathologies such as infections, oxidative stress, inflammation, cancer, diabetes, neurodegeneration, and anxiety [3, 5–8]. These therapeutic characteristics of CAPE have been summarized in this review article.

2. Activities of CAPE

Large number of studies has been conducted on various features of the biological and pharmacological activities of CAPE and its mode of action. Some of them are summarized below.

2.1. Antimicrobial Activity of CAPE. There are many studies which demonstrate the antimicrobial activity of CAPE against Enterococcus faecalis, Listeria monocytogenes, Staphylococcus aureus [9–11], and Haemophilus influenzae showing that RNA, DNA, and cellular proteins are possible targets of CAPE [9, 12]. Thus, dietary intake of CAPE is useful for the treatment of sore throat, common cold, and wound. There is evidence that CAPE possesses promising fungicidal activity on fungi infecting tomato without causing any harm to the fruit [13]. Moreover, poly(lactic-co-glycolic acid) (PLGA) sutures containing CAPE have been proposed to have antibacterial activity against Staphylococcus aureus and Escherichia DH5α bacteria; this activity of CAPE was attributed to the synthesis of reactive oxygen species (ROS)
that destroy the outer membrane of bacteria [14]. In recent studies [15–17], CAPE has been proposed as a valuable inhibitor of HIV-1 integrase; therefore, this polyphenol is believed to be a potential anti-HIV therapy. Fesen et al. reported that the integration step is efficiently inhibited by CAPE than the initial cleavage step by HIV-1 integrase [18]. In addition, CAPE and its esters, in a concentration range of 1.0 to 109.6 mM, have also been tested in an HCV replicon cell line of genotype lb and found effective against replication of hepatitis C virus suggesting it a promising anti-HCV compound [19].

### 2.2. Anti-Inflammatory Activity.

The anti-inflammatory activity of CAPE has also been documented [20, 21] (Table 1). The mode of anti-inflammatory activity of CAPE involves the inhibition of arachidonic acid release from the cell membrane; it, in return, inhibits the COX-1 and COX-2 activity as well as suppresses the activation of gene responsible for COX-2 expression [22–25]. In carrageenin-induced inflammation, CAPE suppresses both exudate volume and leukocytes relocation [26–28].

Moreover, the immunosuppressive behavior of CAPE has been evaluated in T-cells [29] because generally the causative agent for inflammation is T-cells [25]. This discovery revealed the CAPE-mediated inhibition of initial and late steps in T-cell receptor-mediated T-cell activation [28] and thus proposed the mechanistic basis for the immunomodulatory and anti-inflammatory activities of CAPE. Furthermore, inhibition of both interleukin- (IL-) 2 gene transcription and the IL-2 synthesis by CAPE in stimulated T-cells was also observed. In Jurkat cells, binding with DNA and the activities of transcription factors, such as NF-κB, nuclear factor of activated cells (NFAT), and activator protein-1 (AP-1) were also characterized to examine the mode of inhibition of the transcription phase by CAPE [29–32]. The results elaborated the CAPE-mediated inhibition of NF-κB-dependent transcription showing no effect on the disposition of IκkB (cytoplasmic NF-κB inhibitory protein). In CAPE-treated Jurkat cells, there was restricted binding of NF-κB to DNA and transcriptional activity of a Gal4-p65 hybrid protein. In addition, CAPE-mediated inhibition of binding with DNA and transcriptional activity of NFAT in CAPE-treated Jurkat cells was also seen [29].

For the assessment of CAPE effects, Sanghyun and Seok-Jai used human neutrophils activated by lipopolysaccharide [33]. The results of this study elaborated the CAPE-mediated inhibition of the production of TNF-α and IL-6 factors. Moreover, the attenuation of phosphorylation potentials of ERKI/2 and JNK was also observed. As a conclusion, these outcomes show the potential usage of CAPE for controlling inflammation caused by neutrophils.

In CAPE-treated gastric epithelial cell line (AGS), an obstruction was observed in cytokine- and mitogen-provoked NF-κB and AP-1 expression [34]. Additionally, CAPE inhibited the H. pylori-provoked cell proliferation, H. pylori-induced COX-2 expression, and synthesis of the cytokines, TNF-a, and IL-8. These results are potential insights into the anticancer and anti-inflammatory activities of CAPE.

### 2.3. Cytotoxicity of CAPE.

An extensive literature is available regarding cytotoxicity studies of CAPE as documented in Tables 1 and 2. In the presence of CAPE, human pancreatic and colon cancer cells undergo apoptosis [35, 36]. The in vitro and in vivo studies reveal the growth inhibition of C6 glioma cells by CAPE [37].

There are many evidences [38–42] which elaborate the antiproliferation activity of CAPE. For normal cellular proliferation, adequate levels of nuclear factor (NF)-κB activity must be maintained. In some cancers, elevated activation of NF-κB is observed. To obstruct the NF-κB activation phenomenon, CAPE has been proved to be effective chemopreventive agent [38, 42]. Nutritional ingestion of CAPE may thus be valuable for patients whose tumors express steadily elevated levels of activated NF-κB, for instance, squamous head and neck carcinomas. It has been reported that CAPE render antitumor features [43] devoid of causing cytotoxicity to normal cells [44]. Su et al. proposed that cytotoxicity of CAPE is directly related to its apoptotic effect [45].

The antitumor activity of CAPE has been investigated to reveal its influence on cancer development including angiogenesis, tumor invasion, and metastasis. Liao et al. carried out a cytotoxicity study of CAPE in colon adenocarcinoma cells (CT26) and reported a dose-dependent...
Table 3: Applications of caffeic acid phenethyl ester against chemotherapy-induced toxicities.

| Number | Toxicity inducing drugs | Toxicity | Subject | References |
|--------|-------------------------|----------|---------|------------|
| 1      | Doxorubicin toxicity     | Nephrotoxicity | Rats    | [111]     |
| 2      |                        | Cardiotoxicity | Rats    | [112]     |
| 3      |                        | Neuronal oxidant injury | Rats    | [113]     |
| 4      |                        | Medulloblastoma cell toxicity | Human  | [114]     |
| 5      |                        | Nephrotoxicity | Rats    | [63]      |
| 6      |                        | Bone marrow cell toxicity | Rats    | [115]     |
| 7      |                        | Hepatotoxicity  | Rats    | [116]     |
| 8      |                        | Hepatotoxicity  | Rats    | [117]     |
| 9      |                        | Ototoxicity     | Rats    | [114]     |
| 10     |                        | Neuronal oxidant injury | Human  | [118]     |
| 11     |                        | Nephrotoxicity  | Rats    | [119]     |
| 12     |                        | Cerebellar oxidative stress | Rats    | [120]     |
| 13     |                        | Testicular toxicity | Rats    | [121]     |
| 14     |                        | Nephrotoxicity  | Rats    | [122]     |
| 15     |                        | Hepatorenal oxidative injury | Rats  | [123]     |
| 16     |                        | Hepatorenal oxidative injury | Rats  | [124]     |
| 17     |                        | Lung fibrosis   | Rats    | [124, 125]|
| 18     |                        | Hepatotoxicity  | Rats    | [126]     |

decline in cell viability [46]. Moreover, there was reduction in both expression of matrix metalloproteinase and production of vascular endothelial growth factor from CAPE-treated CT26 cells resulting in the reduced angiogenesis and metastasis [47]. These observations provide insight into the promising antimetastatic feature of CAPE. In addition, Song et al. reported that antiangiogenic property of CAPE was also accounted for its anti-inflammatory effect because angiogenesis and chronic inflammation depend on each other [48]. An anti-inflammatory response is obtained by blockage of angiogenesis [49–51]. As far as mode of anticancer activity of CAPE is concerned, CAPE is capable of (i) inhibiting the xanthine oxidase which can metabolicize both purine and pyrimidine bases and obstruct the nucleotide production pathway [52–54]; (ii) suppressing 5-lipoxygenase [55]; (iii) inhibiting the tumor promoter-mediated oxidative responses in the culture of HeLa cells [56]; (iv) inhibiting the azoxymethane-provoked colonic preneoplastic lesions and enzymatic processes related to colon carcinogenesis [44]; (v) inducing apoptosis [57]; and (vi) modulating the redox state of the cells [51, 58–60].

2.4. CAPE against Chemotherapy- and Irradiation-Induced Toxicities. Due to free radical formation and oxidant injury, many drugs used for the treatment of cancer destroy the physiological homeostasis of many organs, such as kidneys and liver [61, 62]. It reduces therapeutic efficacy of anticancer drugs and produces undesired effects, such as doxorubicin, and cisplatin causes nephrotoxicity, while tamoxifen produces hepatotoxicity. Methotrexate activates the NF-κB which causes mucosal barrier injury. These side effects limit their use as anticancer chemotherapy. Table 3 lists various studies conducted to explore the role of CAPE in minimizing undesired effects of some anticancer drugs, that is, doxorubicin, cisplatin, methotrexate, bleomycin, and tamoxifen. The usage of CAPE suppresses free radical formation [63]; thus chemotherapy-induced toxicities are diminished. Moreover, CAPE inhibits the NF-κB factor which amplifies the susceptibility of intestinal epithelial cells to anticancer drugs, preferably methotrexate [64, 65]. So, these studies present CAPE to be an effective adjuvant of chemotherapy for enhancing therapeutic efficacy and diminishing chemotherapy-induced toxicities.

The usage of CAPE against irradiation-induced toxicities of tumor cells has also been done and very promising results are seen (Table 4). Many genes are affected by transcription factor NF-κB resulting in various disorders, such as immune and inflammatory syndromes. The activation of NF-κB induced by irradiation stimulates various undesired effects, such as an inflammatory response in the intestines. Since CAPE has emerged as an effective inhibitor of NF-κB, CAPE has been applied in different animal models and cell lines to understand inflammatory phases after irradiation [66]. Table 4 enlists various studies which suggest that CAPE

Table 4: Applications of caffeic acid phenethyl ester against chemotherapy-induced toxicities of tumor cells.

| Number | Toxicity | Subject | References |
|--------|----------|---------|------------|
| 1      | Lung injury | Rats   | [127]     |
| 2      | Medulloblastoma cell toxicity | Rats   | [128]     |
| 3      | Ileal mucosal toxicity | Rats   | [75]      |
| 4      | Normal lung fibroblast and lung cancer cell line | Rats   | [129]     |
can promisingly avert the development of postirradiation inflammation.

For successful radiotherapy, the application of CAPE in radiosensitization of tumor cells has been studied (Table 5). By ionizing radiation, the increased death of CAPE treated cells has been reported [67]. Since CAPE is an effective inhibitor of NF-κB and a stimulator of the functions of glutathione S-transferase, it drains GSH levels. Subsequently, tumor cells are radiosensitized due to this drainage.

### 2.5. Miscellaneous Activities of CAPE

The studies have demonstrated that CAPE possesses neuroprotective activity [68–71]. CAPE can obstruct apoptosis in cerebellar granule cells [72], reduce ischemia/reperfusion-provoked cerebral injury [73, 74] and spinal cord ischemia/reperfusion injury [75], and avert different toxin-provoked neurotoxicity [69, 76–79]. Moreover, CAPE efficiently suppresses NFκB activation [55], lipid peroxidation activity [38], lipoxygenase activities [80], protein tyrosine kinase activity [81], and ornithine decarboxylase activity [82].

As a result of cellular metabolism, reactive oxygen species (ROS) are generated. The representative examples of ROS include hydrogen peroxide (H\textsubscript{2}O\textsubscript{2}), the superoxide anion, hydroxyl ion, and reactive nitrogen species, especially nitric oxide [83]. The enzymatic processes usually detoxify these ROS [84]. On the other hand, ROS build up if an imbalance is established between their synthesis and degradation resulting in oxidative stress. The excessive ROS can react to the macromolecules such as DNA resulting in some harmful responses [85]. Large research has been done to assess antioxidant role of CAPE [10, 86]. The evidences show that CAPE is potent antioxidant which can scavenge ROS and protect the cell membrane against lipid peroxidation [87–91]. Some other studies elaborate immunomodulator [4, 38, 92], antihypertoxic [93], antiosteogenic [94], and antiatherosclerotic [95] (Table 1) role of CAPE. Moreover, Ucan et al. have proposed the effect of CAPE on bone healing in a rat model [96].

### 3. Conclusion

Considering the preceding literature, CAPE can be suggested to possess various activities, such as antimicrobial, antioxidant, anti-inflammatory, and cytotoxicity activities. The advance investigations are required about the clinical prospective toxicities of CAPE if it is going to be used as a therapeutic agent. Extensive literature is available on some research areas, but still some areas are very much less or not explored; therefore, further investigations to use this common and economic polyphenol for the best therapeutic treatment of ailments are required and proposed.

### Abbreviations

- CAPE: Caffeic acid phenethyl ester
- ROS: Reactive oxygen species
- HIV: Human immunodeficiency virus
- HCV: Hepatitis C virus
- COX: Cyclooxygenase
- IL: Interleukin
- NF-κB: Nuclear factor kappa-light-chain-enhancer of activated B cells
- NFAT: Nuclear factor of activated cells
- AP-1: Activator protein-1
- IBκB: Cytoplasmic NF-κB inhibitory protein
- ERK: Extracellular signal-regulated protein kinases
- JNK: c-Jun NH\textsuperscript{2}-terminal kinase
- TNF: Tumor necrosis factor
- GSH: Glutathione
- H\textsubscript{2}O\textsubscript{2}: Hydrogen peroxide.

### Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

### Acknowledgments

The authors are very thankful to Imran Tariq, Hafiz Muhammad Irfan Nazar, and Kalsoom Farzana for their kind help in the preparation of this review article.

### References

[1] J. Metzner, H. Beckemeier, M. Paintz, and E. Schneidewind, “Zur antimikrobieller Wirksamkeit von Porpolis und Propolisinhaltstoffen,” *Pharmazie*, vol. 34, pp. 97–102, 1979.
[2] N. Bankova, “Chemical diversity of propolis makes it a valuable source of new biologically active compounds,” *Journal ofApiProduct and ApiMedical Science*, vol. 1, pp. 23–28, 2009.
[3] S. Kumazawa, M.-R. Ahn, T. Fujimoto, and M. Kato, “Radical-scavenging activity and phenolic constituents of propolis from different regions of Argentina,” *Natural Product Research*, vol. 24, no. 9, pp. 804–812, 2010.
[4] D. Grunberger, R. Banerjee, K. Eisinger et al., “Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis,” *Experientia*, vol. 44, no. 3, pp. 230–232, 1988.
[5] H.-C. Chen, J.-H. Chen, C. Chang, and C.-J. Shieh, “Optimization of ultrasound-accelerated synthesis of enzymatic caffeic acid phenethyl ester by response surface methodology,” *UltrasonicsSonochemistry*, vol. 18, no. 1, pp. 455–459, 2011.
[6] H.-C. Chen, Y.-Y. Ju, Y.-K. Twu et al., “Optimized enzymatic synthesis of caffeic acid phenethyl ester by RSM,” *New Biotechnology*, vol. 27, no. 1, pp. 89–93, 2010.
A. Kurata, Y. Kitamura, S. Irie et al., “Enzymatic synthesis of caffeic acid phenethyl ester analogues in ionic liquid,” Journal of Biotechnology, vol. 148, no. 2-3, pp. 133–138, 2010.

X. Wang, S. Stavchansky, P. D. Bowman, and S. M. Kerwin, “Cytoprotective effect of caffeic acid phenethyl ester (CAPE) and catechol ring-fluorinated CAPE derivatives against menadione-induced oxidative stress in human endothelial cells,” Bioorganic and Medicinal Chemistry, vol. 14, no. 14, pp. 4879–4887, 2006.

N. Kishimoto, Y. Kakino, K. Iwai, K. Mochida, and T. Fujiita, “In vitro antibacterial, antimutagenic and anti-influenza virus activity of caffeic acid phenethyl esters,” Biocontrol Science, vol. 10, no. 4, pp. 155–161, 2005.

C. Velazquez, M. Navarro, A. Acosta et al., “Antibacterial and free-radical scavenging activities of Sonoran propolis,” Journal of Applied Microbiology, vol. 103, no. 5, pp. 1747–1756, 2007.

A. Kujumgiev, V. Bankova, A. Ignatova, and S. Popov, “Antibacterial activity of propolis, some of its components and their analogs,” Pharmazie, vol. 48, no. 10, pp. 785–786, 1993.

J. Serkedjieva, N. Manolova, and V. Bankova, “Anti-influenza virus effect of some propolis constituents and their analogues (esters of substituted cinnamic acids),” Journal of Natural Products, vol. 55, no. 3, pp. 294–297, 1992.

A. J. Ojeda-Contreras, J. Hernández-Martínez, Z. Domínguez et al., “Utilization of caffeic acid phenethyl ester to control Alternaria alternata rol in tomato (Lycopersicon esculentum Mill.) fruit,” Journal of Phytopathology, vol. 156, no. 3, pp. 164–173, 2008.

H. S. Lee, S. Y. Lee, S. H. Park et al., “Antimicrobial medical suture with caffeic acid phenethyl ester and their in vitro/in vivo biological assessment,” MedChemComm, vol. 4, pp. 777–782, 2013.

T. R. Burke Jr., M. R. Fesen, A. Mazumder et al., “Hydroxylated aromatic inhibitors of HIV-1 integrase,” Journal of Medicinal Chemistry, vol. 38, no. 21, pp. 4171–4178, 1995.

A. A. Johnson, C. Marchand, and Y. Pommier, “HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial,” Current Topics in Medicinal Chemistry, vol. 4, no. 10, pp. 1059–1077, 2004.

Y. Pommier, A. A. Johnson, and C. Marchand, “Integrase inhibitors to treat HIV/AIDS,” Nature Reviews Drug Discovery, vol. 4, no. 3, pp. 236–248, 2005.

M. R. Fesen, K. W. Kohn, F. Leteurtre, and Y. Pommier, “Inhibitors of human immunodeficiency virus integrase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 6, pp. 2399–2403, 1993.

H. Shen, A. Yamashita, M. Nakakoshi et al., “Inhibitory effects of caffeic acid phenethyl ester derivatives on replication of hepatitis C virus,” PloS ONE, vol. 8, no. 12, Article ID e82299, 2013.

S.-Y. Io, N. Lee, S.-M. Hong, H. H. Jung, and S.-W. Chae, “Caffeic acid phenethyl ester inhibits diesel exhaust particle-induced inflammation of human middle ear epithelial cells via NOX4 inhibition,” Annals of Otology, Rhinology, and Laryngology, vol. 122, pp. 595–600, 2013.

F. M. da Cunha, D. Duma, J. Assrey et al., “Caffeic acid derivatives: in vitro and in vivo anti-inflammatory properties,” Free Radical Research, vol. 38, no. 11, pp. 1241–1253, 2004.

P. Michaluart, J. L. Masferrer, A. M. Carothers et al., “Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase-2 in human oral epithelial cells and in a rat model of inflammation,” Cancer Research, vol. 59, no. 10, pp. 2347–2352, 1999.

Z. Orban, N. Mitsiades, T. R. Burke Jr., M. Tsokos, and G. P. Chrousos, “Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation,” NeuroImmunoModulation, vol. 7, no. 2, pp. 99–105, 2000.

O. K. Mirzoeva and P. C. Calder, “The effect of propolis and its components on eicosanoid production during the inflammatory response,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 6, pp. 441–449, 1996.

K. W. Lee, K.-S. Chun, J.-S. Lee, K.-S. Kang, Y.-J. Surh, and H. J. Lee, “Inhibition of cyclooxygenase-2 expression and restoration of gap junction intercellular communication in H-ras-transformed rat liver epithelial cells by caffeic acid phenethyl ester,” Annals of the New York Academy of Sciences, vol. 1030, pp. 501–507, 2004.

F. Borrelli, P. Maffia, L. Pinto et al., “Phytochemical compounds involved in the anti-inflammatory effect of propolis extract,” Fitoterapia, vol. 73, no. 1, pp. 553–563, 2002.

M. Gabor and Z. Razga, “Effect of benzopyrone derivatives on simultaneously induced croton oil ear oedema and carrageenin paw oedema in rats,” Acta Physiologica Hungarica, vol. 77, no. 3–4, pp. 197–207, 1991.

G. M. Raso, R. Meli, G. di Carlo, M. Pacilio, and R. di Carlo, “Inhibition of inducible nitric oxide synthase and cyclooxygenase-2 expression by flavonoids in macrophage J774A.1,” Life Sciences, vol. 68, no. 8, pp. 921–931, 2001.

W.-X. Zhao, L. Wang, J.-L. Yang, L.-Z. Li, W.-M. Xu, and T. Li, “Caffeic acid phenethyl ester attenuates pro-inflammatory and fibrogenic phenotypes of LPS-stimulated hepatic stellate cells through the inhibition of NF-κB signaling,” Journal of Pharmacology, vol. 33, pp. 687–694, 2014.

S. Akyol, M. Acar, Z. N. Ünal et al., “The effects of caffeic acid phenethyl ester (CAPE), royal jelly, and curcumin on gene expression of ADAMTS-1,-5, and -9 in OUMS-27 chondrosarcoma cells: a preliminary study,” Annals of Paediatric Rheumatology, vol. 2, pp. 27–37, 2013.

J.-Y. Lee, H.-J. Choi, T.-W. Chung, C.-H. Kim, H.-S. Jeong, and K.-T. Ha, “Caffeic acid phenethyl ester inhibits alpha-melanocyte stimulating hormone-induced melanin synthesis through suppressing transcriptional activity of microphthalmia-associated transcription factor,” Journal of Natural Products, vol. 76, no. 8, pp. 1399–1405, 2013.

C. P. P. Chuu, H. P. Lin, M. F. Ciaccio et al., “Caffeic acid phenethyl ester suppresses the proliferation of human prostate cancer cells through inhibition of p70S6K and Akt signaling networks,” Cancer Prevention Research, vol. 5, no. 5, pp. 788–797, 2012.

K. Sanghyum and K. Seok-Jai, “Effect of caffeic acid phenethyl ester on phagocytosis of septic neutrophil,” Critical Care Medicine, vol. 40, no. 12, 2012.

M. M. M. Abdel-Latif, H. J. Windle, B. S. El Homasany, K. Sabra, and D. Kelleher, “Caffeic acid phenethyl ester modulates Heli-co bacter pylori-induced nuclear factor-kappa B and activator protein-1 expression in gastric epithelial cells,” British Journal of Pharmacology, vol. 146, no. 8, pp. 1139–1147, 2005.

M.-J. Chen, W.-H. Chang, C.-C. Lin et al., “Caffeic acid phenethyl ester induces apoptosis of human pancreatic cancer cells involving caspase and mitochondrial dysfunction,” Pancreatology, vol. 8, no. 6, pp. 566–576, 2008.
[36] D. Xiang, D. Wang, Y. He et al., “Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the β-catenin/T-cell factor signaling,” Anti-Cancer Drugs, vol. 17, no. 7, pp. 753–762, 2006.

[37] H.-C. Kuo, W.-H. Kuo, Y.-J. Lee, W.-L. Lin, F.-P. Chou, and T.-H. Tseng, “Inhibitory effect of caffeic acid phenethyl ester on the growth of C6 glioma cells in vitro and in vivo,” Cancer Letters, vol. 234, no. 2, pp. 199–208, 2006.

[38] K. Natarajan, S. Singh, T. R. Burke Jr., D. Grunberger, and B. B. Aggarwal, “Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-κB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 17, pp. 9090–9095, 1996.

[39] L. Zhang, H. Zhang, X. Zheng et al., “Structural basis for the inhibition of AKR1B10 by caffeic acid phenethyl ester (CAPE),” ChemMedChem, vol. 9, no. 4, pp. 706–709, 2014.

[40] H. C. Ho, H. C. Chang, C. T. Ting, C. Y. Kuo, and V. C. Yang, “Caffeic acid phenethyl ester inhibits proliferation and migration, and induces apoptosis in platelet-derived growth factor-BB-stimulated human coronary smooth muscle cells,” Journal of Vascular Research, vol. 49, no. 1, pp. 24–32, 2011.

[41] T. Dorai and B. B. Aggarwal, “Role of chemopreventive agents in cancer therapy,” Cancer Letters, vol. 215, no. 2, pp. 129–140, 2004.

[42] A. C. Bharti and B. B. Aggarwal, “Nuclear factor-kappa B and cancer: its role in prevention and therapy,” Biochemical Pharmacology, vol. 64, no. 5-6, pp. 883–888, 2002.

[43] P. Komericki and B. Kränke, “Maculopapular exanthem from propolis: case report and review of systemic cutaneous and non-cutaneous reactions,” Contact Dermatitis, vol. 61, no. 6, pp. 353–355, 2009.

[44] K. Frenkel, H. Wei, R. Bhimani et al., “Inhibition of tumor promoter-mediated processes in mouse skin and bovine lens by caffeic acid phenethyl ester,” Cancer Research, vol. 53, no. 6, pp. 1255–1261, 1993.

[45] Z.-Z. Su, J. Lin, M. Prewett, N. I. Goldstein, and P. B. Fisher, “Apoptosis mediates the selective toxicity of caffeic acid phenethyl ester (CAPE) toward oncogene-transformed rat embryo fibroblast cells,” Anticancer Research, vol. 15, no. 5 B, pp. 1841–1848, 1995.

[46] H.-F. Liao, Y.-Y. Chen, J.-J. Liu et al., “Inhibitory effect of caffeic acid phenethyl ester on angiogenesis, tumor invasion, and metastasis,” Journal of Agricultural and Food Chemistry, vol. 51, no. 27, pp. 7907–7912, 2003.

[47] M. L. Khalil, “Biological activity of bee propolis in health and disease,” Asian Pacific Journal of Cancer Prevention, vol. 7, no. 1, pp. 22–31, 2006.

[48] Y. S. Song, E.-H. Park, J. I. Kyung, and C. Jin, “Inhibition of angiogenesis by propolis,” Archives of Pharmacal Research, vol. 25, no. 4, pp. 500–504, 2002.

[49] W.-L. Lin, W.-H. Liang, Y.-J. Lee, S.-K. Chuang, and T.-H. Tseng, “Antitumor progression potential of caffeic acid phenethyl ester involving p53NTR in C6 glioma cells,” Chemico-Biological Interactions, vol. 188, no. 3, pp. 607–615, 2010.

[50] N. Oršolić and I. Bašić, “Water-soluble derivative of propolis and its polyphenolic compounds enhance tumoricidal activity of macrophages,” Journal of Ethnopharmacology, vol. 102, no. 1, pp. 37–45, 2005.

[51] G. Basini, L. Baioni, S. Bussolati et al., “Antiangiogenic properties of an unusual benzo[k]xanthene lignan derived from CAPE (Caffeic Acid Phenethyl Ester),” Investigational New Drugs, vol. 30, no. 1, pp. 186–190, 2012.

[52] G. Ozturk, Z. Ginis, S. Akyol, G. Erden, A. Gurel, and O. Akyol, “The antitumor mechanism of caffeic acid phenethyl ester (CAPE): review of melanomas, lung and prostate cancers,” European Review for Medical and Pharmacological Sciences, vol. 16, pp. 2064–2068, 2012.

[53] H. M. Eid, D. Vallerand, A. Muhammad, T. Durst, P. S. Haddad, and L. C. Martineau, “Structural constraints and the importance of lipophilicity for the mitochondrial uncoupling activity of naturally occurring caffeic acid esters with potential for the treatment of insulin resistance,” Biochemical Pharmacology, vol. 79, no. 3, pp. 444–454, 2010.

[54] T. Wang, L. X. Chen, W. M. Wu, Y. Long, and R. Wang, “Potential cytoprotection: antioxidant defence by caffeic acid phenethyl ester against free radical-induced damage of lipids, DNA, and proteins,” Canadian Journal of Physiology and Pharmacology, vol. 86, no. 5, pp. 279–287, 2008.

[55] G. F. Sud‘ina, O. K. Mirzoeva, M. A. Pushkareva, G. A. Korshunova, N. V. Sumbatyan, and S. D. Varfolomeev, “Caffeic acid phenethyl ester as a lipooxygenase inhibitor with antioxidant properties,” FEBS Letters, vol. 329, no. 1-2, pp. 21–24, 1993.

[56] R. S. Bhimani, W. Troll, D. Grunberger, and K. Frenkel, “Inhibition of oxidative stress in HeLa cells by chemopreventive agents,” Cancer Research, vol. 53, no. 18, pp. 4528–4533, 1993.

[57] M. Nomura, A. Kaji, W. Ma, K. Miyamoto, and Z. Dong, “Suppression of cell transformation and induction of apoptosis by caffeic acid phenethyl ester,” Molecular Carcinogenesis, vol. 31, no. 2, pp. 83–89, 2001.

[58] C. Chiao, A. M. Carothers, D. Grunberger, G. Solomon, G. A. Preston, and J. C. Barrett, “Apoptosis and altered redox state induced by caffeic acid phenethyl ester (CAPE) in transformed rat fibroblast cells,” Cancer Research, vol. 55, no. 16, pp. 3576–3583, 1995.

[59] S. K. Kudugunti, H. Thorsheim, M. S. Yousef, L. Guan, and M. Y. Moridani, “The metabolic bioactivation of caffeic acid phenethyl ester (CAPE) mediated by tyrosinase selectively inhibits glutathione S-transferase,” Chemico-Biological Interactions, vol. 192, no. 3, pp. 243–256, 2011.

[60] S. K. Kudugunti, N. M. Vad, E. Egkobgo, and M. Y. Moridani, “Efficacy of Caffeic Acid Phenethyl Ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice,” Investigational New Drugs, vol. 29, no. 1, pp. 52–62, 2011.

[61] G. M. Sulaiman, A. A. Al-Amiery, and R. Bagnati, “Theoretical, antioxidant and cytotoxic activities of caffeic acid phenethyl ester and chrysin,” International Journal of Food Sciences and Nutrition, vol. 65, pp. 101–105, 2014.

[62] S. Akyol, Z. Ginis, F. Armutcu, G. Ozturk, M. Ramazan Yigitoglu, and O. Akyol, “The potential usage of caffeic acid phenethyl ester (CAPE) against chemotherapy-induced and radiotherapy-induced toxicity,” Cell Biochemistry and Function, vol. 30, no. 5, pp. 438–443, 2012.

[63] S. Özen, O. Akyol, M. Iraz et al., “Role of caffeic acid phenethyl ester, an active component of propolis, against cisplatin-induced nephrotoxicity in rats,” Journal of Applied Toxicology, vol. 24, no. 1, pp. 27–35, 2004.

[64] A. Kizilay, M. T. Kalcioğlu, E. Ozerol et al., “Caffeic acid phenethyl ester ameliorated otoxicity induced by cisplatin in rats,” Journal of Chemotherapy, vol. 16, no. 4, pp. 381–387, 2004.

[65] B. van’t Land, N. M. A. Blijlevens, J. Marteijn et al., “Role of curcumin and the inhibition of NF-κB in the onset of chemotherapy-induced mucosal barrier injury,” Leukemia, vol. 18, no. 2, pp. 276–284, 2004.
hepatorenal oxidative injury in rats,” *Journal of Pharmacy and Pharmacology*, vol. 63, no. 12, pp. 1566–1571, 2011.

[124] H. Özyurt, S. Soğut, Z. Yildirim et al., “Inhibitory effect of caffeic acid phenethyl ester on bleomycine-induced lung fibrosis in rats,” *Clinica Chimica Acta*, vol. 339, no. 1-2, pp. 65–75, 2004.

[125] A. Larki, A. A. Hemmati, A. Arzi, M. G. Borujerdnia, S. Esmaeilzadeh, and M. R. Z. Karami, “Regulatory effect of caffeic acid phenethyl ester on type I collagen and interferon-gamma in bleomycin-induced pulmonary fibrosis in rat,” *Research in Pharmaceutical Sciences*, vol. 8, no. 4, pp. 243–252, 2013.

[126] A. A. Albukhari, H. M. Gashlan, H. A. El-Beshbishy, A. A. Nagy, and A. B. Abdel-Naim, “Caffeic acid phenethyl ester protects against tamoxifen-induced hepatotoxicity in rats,” *Food and Chemical Toxicology*, vol. 47, no. 7, pp. 1689–1695, 2009.

[127] O. G. Yıldız, S. Soyuer, R. Saraymen, and C. Eroglu, “Protective effects of caffeic acid phenethyl ester on radiation induced lung injury in rats,” *Clinical and Investigative Medicine*, vol. 31, no. 5, pp. E242–E247, 2008.

[128] Y.-Y. Lee, C.-L. Kao, P.-H. Tsai et al., “Caffeic acid phenethyl ester preferentially enhanced radiosensitizing and increased oxidative stress in medulloblastoma cell line,” *Child’s Nervous System*, vol. 24, no. 9, pp. 987–994, 2008.

[129] M.-F. Chen, P. C. Keng, P.-Y. Lin, C.-T. Yang, S.-K. Liao, and W.-C. Chen, “Caffeic acid phenethyl ester decreases acute pneumonitis after irradiation in vitro and in vivo,” *BMC Cancer*, vol. 5, article 158, 2005.

[130] M.-F. Chen, C.-T. Wu, Y.-J. Chen, P. C. Keng, and W.-C. Chen, “Cell killing and radiosensitization by Caffeic Acid Phenethyl Ester (CAPE) in lung cancer cells,” *Journal of Radiation Research*, vol. 45, no. 2, pp. 253–260, 2004.